Activity Overview
This educational activity is an archive of the live presentation held on May 29, 2026.
For more information about this educational activity, the faculty,
and disclosures, please click here.
Target Audience
This educational activity is directed toward medical oncologists,
thoracic surgeons, pulmonologists, radiation oncologists, pathologists, nurse
practitioners, physician assistants, pharmacists, oncology nurses, and other
health care providers who manage patients with early-stage non-small cell lung
cancer (NSCLC).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate contemporary clinical trial evidence supporting immunotherapy across stages I-III NSCLC
- Incorporate multidisciplinary assessment and molecular/biologic features into evidence-based, individualized treatment decisions for patients with resectable and unresectable early-stage NSCLC
- Apply best practices for mitigating and managing immune-related adverse effects in patients with early-stage NSCLC
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
